The CDMO, which specializes in sterile injectables, is investing in a dual-continent expansion strategy at its sites in Bloomington, Indiana and Halle/Westfalen, Germany.
Sharon Anderson, Vice President for Scientific Affairs at the Alliance for Regenerative Medicine, shares her perspective on the evolving cell and gene therapy landscape.
The company’s proprietary manufacturing enhancers reportedly boost adeno-associated virus production efficiency, while maintaining product integrity across scales.
The newly formed company from the businesses of Mallinckrodt and Endo, which merged in July 2025, will focus on branded therapeutics for rare and underserved conditions.
